Understanding the Cartagena Protocol: Safeguarding Biodiversity in the Age of Biotechnology

Modern biotechnology has transformed agriculture, medicine, and industry in remarkable ways. But as scientists develop new living modified organisms (LMOs)-from pest-resistant crops to bioengineered microorganisms-a critical question arises: how do we make sure these innovations don’t harm the natural ecosystems they interact with? That’s exactly the question the Cartagena Protocol on Biosafety was designed to answer. Adopted in January 2000 and entering into force on 11 September 2003, this legally binding international treaty remains the cornerstone of global biosafety governance.

What is the Cartagena Protocol on Biosafety? 🔗

The Cartagena Protocol on Biosafety is a supplementary agreement to the Convention on Biological Diversity (CBD). It was named after Cartagena, Colombia, where negotiations were originally expected to conclude in 1999. After delays, the Protocol was finalized and adopted in Montreal, Canada, on 29 January 2000, with 135 countries present.

The Protocol’s core purpose is to protect biological diversity from risks that may arise due to the cross-border movement of LMOs produced through modern biotechnology. An LMO, as defined under the Protocol, is any living organism with a novel combination of genetic material obtained through techniques like recombinant DNA technology. The terms LMO and genetically modified organism (GMO) are essentially interchangeable in this context. As of 2020, the Protocol had 173 parties, including 170 UN member states and the European Union.

Goals and key provisions of the Cartagena Protocol 🔗

The Protocol has one overarching goal: to ensure an adequate level of protection during the safe transfer, handling, and use of LMOs that could negatively impact biodiversity or human health. To achieve this, it established several important mechanisms.

Advance Informed Agreement (AIA) procedure 🔗

The AIA is the backbone of the Protocol. It applies to the first intentional transboundary movement of LMOs meant for release into the environment-such as genetically modified seeds, fish, or microorganisms for bioremediation. The process works in four stages: notification by the exporting party, acknowledgment of receipt by the importing party, a decision-making procedure, and an opportunity for review of decisions. This ensures that importing countries can assess potential risks before agreeing to accept LMO imports.

Importantly, the importing country must make its decision within 270 days of receiving the notification. If a country decides to reject an import, it must provide its reasons based on a scientific risk assessment.

Simplified procedure for LMOs used as food, feed, or processing 🔗

Not all LMOs go through the AIA procedure. LMOs intended for direct use as food, feed, or processing (known as LMOs-FFP)-such as genetically modified corn, soybean, or wheat-follow a simpler process. When a country makes a final decision about the domestic use of such an LMO, it must notify other parties through the Biosafety Clearing-House (BCH) within 15 days. Developing countries that lack domestic regulatory frameworks may rely on the Protocol’s own risk assessment standards to make import decisions.

Biosafety Clearing-House (BCH) 🔗

The BCH is an internet-based platform administered by the CBD Secretariat. It facilitates the exchange of scientific, technical, environmental, and legal information on LMOs between countries. Information hosted on the BCH includes national biosafety laws, summaries of risk assessments, and final decisions on LMO imports or releases. The BCH helps countries build the capacity to manage biotechnology safely and makes informed decision-making accessible even to nations with limited scientific infrastructure.

Safe handling, transport, and identification 🔗

The Protocol requires all parties to ensure that LMOs undergoing transboundary movement are handled, packaged, and transported safely. Shipments must include documentation identifying the LMOs, specifying any special handling requirements, and providing contact details for further information. These requirements help prevent accidental environmental release during transit.

The precautionary principle: acting before harm occurs 🔗

One of the most significant aspects of the Cartagena Protocol is its adoption of the precautionary approach, rooted in Principle 15 of the Rio Declaration on Environment and Development (1992). The core idea is straightforward: where there are threats of serious or irreversible damage, lack of full scientific certainty should not be used as a reason for postponing protective measures.

In practical terms, this means a country can restrict or ban imports of an LMO even if there isn’t conclusive scientific evidence that the organism is harmful-as long as there is a reasonable basis for concern. The Protocol explicitly states that insufficient scientific knowledge should not be interpreted as indicating an absence of risk.

This provision was groundbreaking in international environmental law. According to the International Institute for Sustainable Development (IISD), the Protocol’s import decision provisions represent one of the most explicit examples of operationalization of the precautionary approach in any multilateral environmental agreement.

Why does the precautionary approach matter? 🔗

Biotechnology advances rapidly, and ecological impacts can take years-sometimes decades-to become apparent. Gene flow from a modified crop to wild relatives, for instance, might not show visible consequences immediately. The precautionary approach allows governments to act proactively rather than waiting for damage to occur and then trying to reverse it. This is especially important for biodiversity-rich developing countries that may lack the resources for extensive long-term monitoring.

Risk assessment: the scientific foundation 🔗

While the precautionary approach gives countries flexibility, the Protocol also emphasizes that decisions on LMO imports must be grounded in scientific risk assessment. Annex III of the Protocol lays out detailed guidelines on how risk assessments should be conducted. These include general principles, methodology, and specific points to consider.

Key requirements of risk assessment under the Protocol include:

Case-by-case evaluation: Each LMO must be assessed individually based on its specific characteristics, intended use, and the receiving environment. There is no blanket approval or rejection of LMOs as a category.

Comparison with non-modified organisms: Risks from an LMO should be evaluated in the context of risks posed by the unmodified parent organism in the same environment. This comparative approach helps identify what additional risks, if any, the genetic modification introduces.

Scientific rigour: Assessments must follow recognized scientific techniques and use relevant, reliable data. The quality of scientific information, how uncertainty is identified, and how it is addressed throughout the process are all critical considerations.

Transparency: Results of risk assessments must be made available through the BCH, enabling other countries and stakeholders to access and review the findings.

Implementation in India 🔗

India ratified the Cartagena Protocol on 23 January 2003. The Ministry of Environment, Forest and Climate Change (MoEFCC) serves as the Competent National Authority for implementing the Protocol’s provisions. India was actually an early mover in biosafety regulation, having established its biosafety regulatory framework as far back as 1989-well before the Protocol came into force.

India’s regulatory framework for biosafety 🔗

India’s biosafety governance operates through several key bodies and regulations. The Genetic Engineering Appraisal Committee (GEAC) is the apex regulatory body that oversees the approval, research, testing, and commercialization of genetically modified organisms. In Indian regulations, the terms genetically engineered organism and genetically modified organism are used interchangeably with LMOs.

India has developed comprehensive guidelines for risk assessment and risk management of GMOs. It also established the India Biosafety Clearing-House, as required under Article 20 of the Cartagena Protocol, to facilitate the exchange of scientific, technical, and legal information on LMOs. India has also submitted all its national reports as required under the Protocol’s review process.

The country has also been a significant host for Protocol discussions. India hosted the sixth meeting of the Conference of the Parties serving as the Meeting of the Parties (COP-MOP 6) in Hyderabad in October 2012, where several important decisions were adopted, including work on risk assessment guidance and socio-economic considerations.

Capacity building initiatives 🔗

India has benefited from Global Environment Facility (GEF)-supported projects aimed at strengthening biosafety capacity. These projects have focused on risk assessment and risk management, handling and transport protocols, socio-economic considerations, and public awareness-all aligned with the Protocol’s emphasis on helping developing nations build the institutional capacity to regulate biotechnology effectively.

Global impact and examples of biosafety regulation 🔗

The Cartagena Protocol has had a substantial impact on how countries around the world regulate LMOs, particularly in the developing world.

The European Union 🔗

The EU has been one of the strongest advocates of the precautionary principle in biosafety regulation. It implements the Protocol’s requirements through Regulation (EC) 1946/2003 on transboundary movement of genetically modified organisms. The EU’s approach requires exporters to notify the competent authority of the importing country before any first intentional shipment of a GMO intended for environmental release. In 2015, the EU adopted Directive (EU) 2015/412, which allows individual member states to ban GMO cultivation on their territory even without citing new scientific evidence of risk-a significant expansion of precautionary powers.

African nations 🔗

For many African countries, the Protocol has been instrumental in developing national biosafety frameworks. As the African Union Development Agency (AUDA-NEPAD) has documented, the Protocol provides minimum standards that parties can build upon with more protective national legislation. Many African nations have enacted national biosafety laws directly modelled on the Protocol’s provisions, enabling them to manage LMO imports in a structured, science-based manner.

Trade disputes and the WTO 🔗

The Protocol’s relationship with World Trade Organization (WTO) rules has been a source of tension. In 2003, the United States, Canada, and Argentina challenged the EU’s effective moratorium on GMO approvals before the WTO, arguing it violated trade obligations. The WTO dispute resolution panel sided with the complainants, finding that the EU’s delays in processing approvals breached its obligations under the Agreement on Sanitary and Phytosanitary Measures (SPS Agreement). This case highlighted the ongoing challenge of balancing trade liberalization with environmental and health precaution-a tension the Protocol’s preamble explicitly acknowledges by stating that trade and environmental agreements should be mutually supportive.

Balancing innovation and safety 🔗

The Cartagena Protocol does not oppose biotechnology. It recognizes that modern biotechnology holds enormous potential for human well-being-from developing drought-resistant crops to creating organisms that can clean up environmental pollution. What the Protocol insists on is that this potential must be realized responsibly.

Socio-economic considerations 🔗

Article 26 of the Protocol allows importing countries to take socio-economic factors into account when making decisions about LMO imports, provided these decisions are consistent with their other international obligations. This is significant because it acknowledges that the impact of LMOs extends beyond biology. Concerns that GM crop imports could displace traditional farming practices, affect indigenous communities, or create economic dependency on seed companies are legitimate considerations under the Protocol’s framework.

Supporting developing countries 🔗

The Protocol promotes international cooperation specifically to help developing countries build the scientific and institutional capacity needed to use biotechnology safely. It encourages member governments to assist with scientific and technical training, technology transfer, and financial resources. This capacity-building dimension is essential because without adequate regulatory infrastructure, developing nations risk either accepting LMOs without proper assessment or rejecting potentially beneficial technology out of caution.

The Nagoya-Kuala Lumpur Supplementary Protocol 🔗

To further strengthen the biosafety framework, the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress was adopted in 2010 and entered into force in 2018. This supplementary agreement addresses a gap in the original Protocol by establishing rules for what happens when LMOs cause damage to biodiversity. It requires parties to take response measures in the event of such damage and provides a framework for holding responsible parties accountable. The Supplementary Protocol reinforces the Cartagena Protocol by adding a layer of accountability that was previously missing.

Adapting to new biotechnologies 🔗

As biotechnology continues to evolve-with developments like gene editing (CRISPR), synthetic biology, and gene drives-the Protocol faces the challenge of remaining relevant. These new techniques raise questions that weren’t fully anticipated when the Protocol was negotiated in the late 1990s. Whether organisms modified through gene editing qualify as LMOs under the Protocol’s definitions, and how the risk assessment framework should apply to them, are active areas of discussion among parties.

Why the Cartagena Protocol still matters 🔗

More than two decades after it entered into force, the Cartagena Protocol remains the only legally binding international agreement specifically dedicated to biosafety. It has contributed to the development of national biosafety regulatory frameworks in over 170 countries, established international norms for risk assessment and information sharing, and created a platform for dialogue between exporting and importing nations with very different levels of scientific capacity.

The Protocol’s strength lies in its balance. It doesn’t ban biotechnology. It doesn’t create unreasonable trade barriers. What it does is establish a rule-based international system where countries have the right-and the tools-to make informed decisions about LMOs based on science, precaution, and their own national circumstances.

For a world increasingly dependent on biotechnological solutions to problems like food insecurity, climate change, and disease, this kind of framework is not just useful-it is essential. The challenge going forward is ensuring that the Protocol’s provisions keep pace with the speed of scientific innovation while continuing to protect the biodiversity that sustains all life on Earth.

What do you think? As biotechnology advances faster than regulatory frameworks can adapt, is the precautionary approach still the right strategy for managing LMOs-or does it risk slowing down innovations that could address critical global challenges like hunger and climate change?

References

1. https://en.wikipedia.org/wiki/Cartagena_Protocol_on_Biosafety
2. https://www.cbd.int/
3. https://www.nepad.org/content/background-cartagena-protocol-biosafety
4. https://www.isaaa.org/resources/publications/pocketk/8/default.asp
5. https://www.iisd.org/articles/deep-dive/precautionary-principle
6. https://www.iisd.org/articles/deep-dive/biosafety-ensuring-safe-use-modern-biotechnologies
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4720779/
8. https://moef.gov.in/en/cartagena-protocol-on-biosafety-cpb/
9. http://geacindia.gov.in/india-bch.aspx
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC8132481/
11. https://www.canada.ca/en/environment-climate-change/corporate/international-affairs/partnerships-organizations/biosafety-cartagena-protocol.html